출판 : MarketsandMarkets（마켓츠앤마켓츠）출판년월 : 2022년07월
조직 진단(Tissue Diagnostics) 시장 : 제품(항체, 키트, 슬라이드 염색 시스템, 조직 처리 시스템), 기술(ISH, IHC, 특수 염색), 질환(유방암, NSCLC, 림프종), 최종 사용자(병원, 연구소) – 2027년까지의 세계 예측
Tissue Diagnostics Market by Product(Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology(ISH, IHC, Special Staining), Disease(Breast Cancer, NSCLC, Lymphoma), End User (Hospitals, Research Laboratories) – Global Forecast to 2027
| 페이지수 | 240 |
| 도표수 | 229 |
| 구성 | 영문조사보고서 |
| 가격 |
The global Tissue Diagnostics market is growing at a CAGR of 6.6% during and it is expected to reach USD 7.3 billion by 2027 from USD 5.3 billion in 2022, during the forecast period. The expansion of this market is majorly due to rising prevalence of neoplastic cases as well as high demand of oncology screening, However, Lack of skilled professionals is one of the challenge for which may inhibit the growth of this market.
세계 조직 진단 시장은 이 기간 동안 6.6%의 CAGR로 성장하고 있으며 예측 기간 동안 2022년 53억 달러에서 2027년 73억 달러에 이를 것으로 예상됩니다. 이 시장의 확장은 주로 종양 검진의 높은 수요와 신생물 사례의 증가로 인한 것이지만 숙련된 전문가의 부족은 이 시장의 성장을 저해할 수 있는 과제 중 하나입니다.
“The Slide-Staining Systems in instruments is projected to grow at CAGR of 7.4% from 2022 to 2027”
Based on the product, the tissue diagnostics market is classified into tissue diagnostics consumables (Antibodies, Kits, Reagents, Probes) and tissue diagnostics Instruments (Slide-staining Systems, Scanners, Tissue-processing Systems, Other Instruments). The growth of this market is majorly driven by the factors such as benefits of automation, the greater capacity of slide staining systems, and the elimination of manual errors, and delivering high throughput staining capabilities for histology laboratories.
“Asia Pacific is estimated to register the highest CAGR during the forecast period.”
In this report, the tissue diagnostics market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by the economic growth in the countries of this region, large population base, the rising prevalence of chronic diseases, the rising standard of living, growing demand for quality medical care, increasing healthcare spending, increasing government initiatives, and rising awareness regarding the use of tissue diagnostic tests
Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)
• By Designation: C-level (30%), Director-level (34%), and Others (36%)
• By Region: North America (40%), Europe (28%), AsiaPacific (20%), and Rest of the World(12%)
List of Companies Profiled in the Report
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Danaher Corporation (US)
• Thermo Fisher Scientific, Inc (US)
• Abbott (US)
• Agilent Technologies Inc. (US)
• Merck KGAA (Germany)
• SAKURA FINETEK JAPAN CO., LTD (Japan)
• Abcam Plc. (UK)
• Becton, Dickinson and Company (BD) (US)
• Bio SB (US)
• Biogenix (US)
• Cell Signaling Technology, Inc (US)
• Histo-Line Laboratories (Italy)
• SLEE Medical GMBH (Germany)
• Hologic Inc. (US).
• Jinhua YIDI Medical Appliance Co. Ltd (China)
• MEDITE MEDICAL GMBH (Germany)
• Cellpath Ltd (UK)
• Amos scientific Pty Ltd (Australia)
• Dipath S.P.A (Italy)
• KFBIO KONFOONG BIOINFORMATION TECH CO
• LTD (China), Diagnostic BioSystems Inc. (US)
• 3DHISTECH LTD (Hungary)
• RWD LIFE SCIENCE CO., LTD. (China)
• Dakewe Biotech Co., Ltd. (China)
Research Coverage:
This report studies the tissue diagnostics market based on product, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total tissue diagnostics market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on tissue diagnostics products offered by the top 25 players in the tissue diagnostics market. The report analyzes the tissue diagnostics market by product, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the tissue diagnostics market
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the tissue diagnostics market
목차
TABLE OF CONTENTS
1 INTRODUCTION (Page No. – 29)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 GEOGRAPHIC SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. – 34)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: DANAHER CORPORATION
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.1 GROWTH FORECAST
FIGURE 7 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
FIGURE 8 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
3 EXECUTIVE SUMMARY (Page No. – 47)
FIGURE 10 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 11 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 12 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2022 VS. 2027 (USD MILLION)
FIGURE 13 TISSUE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 14 GEOGRAPHIC SNAPSHOT OF GLOBAL TISSUE DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS (Page No. – 51)
4.1 TISSUE DIAGNOSTICS MARKET OVERVIEW
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
4.2 TISSUE DIAGNOSTICS MARKET, BY PRODUCT
FIGURE 16 EQUIPMENT IN TISSUE DIAGNOSTICS SEGMENT TO REGISTER HIGHEST CAGR DURING 2022-2027.
4.3 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE & COUNTRY
FIGURE 17 GASTRIC CANCER SEGMENT TO DOMINATE ASIA PACIFIC MARKET IN 2022
4.4 GEOGRAPHIC SNAPSHOT OF TISSUE DIAGNOSTICS MARKET
FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. – 54)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of cancer
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
5.2.1.2 Growing demand for digital pathology
5.2.1.3 Increasing healthcare expenditure
FIGURE 20 CURRENT HEALTH EXPENDITURE PER CAPITA
FIGURE 21 CURRENT HEALTH EXPENDITURE (% OF GDP)
5.2.1.4 Developing infrastructure for cancer diagnosis
5.2.1.5 Increasing availability of reimbursements
5.2.1.6 Growing private diagnostics centers globally
5.2.1.7 Rising geriatric population with subsequent growth in chronic and infectious diseases
FIGURE 22 ESTIMATED INCREASE IN CANCER INCIDENCE (IN MILLION)
FIGURE 23 ESTIMATED DEATHS OF CANCER (IN MILLION)
5.2.2 RESTRAINTS
5.2.2.1 High degree of consolidation
5.2.3 OPPORTUNITIES
5.2.3.1 Significant opportunities in BRICS countries
FIGURE 24 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012–2019
5.2.3.2 Growing demand for personalized medicines
FIGURE 25 GROWTH OF PERSONALIZED MEDICINES APPROVED BY FDA, 2015–2021
5.2.3.3 Increasing number of clinical trials pertaining to cancer drugs
FIGURE 26 NUMBER OF ARTICLES RELATED TO TISSUE DIAGNOSTICS PUBLISHED ON PUBMED (2011–2021)
5.2.3.4 Emerging economies to offer significant opportunities to companies
5.2.4 CHALLENGES
5.2.4.1 Lack of skilled professionals
TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
5.2.4.2 Availability of refurbished products
5.2.4.3 Product failures and recalls
5.2.4.4 Stringent regulatory requirements
5.2.4.5 Lack of infrastructure and low awareness in middle and low income countries
5.2.5 TRENDS
5.2.5.1 Increasing number of reagent rental agreements
5.2.5.2 Increasing usage of AI in histopathology
5.3 COVID-19 IMPACT ON TISSUE DIAGNOSTICS MARKET
5.4 RANGES/SCENARIOS
5.4.1 TISSUE DIAGNOSTICS MARKET
FIGURE 27 PESSIMISTIC SCENARIO
FIGURE 28 OPTIMISTIC SCENARIO
FIGURE 29 REALISTIC SCENARIO
5.5 VALUE CHAIN ANALYSIS
FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 31 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.7 TECHNOLOGY ANALYSIS
5.8 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 INTENSITY OF COMPETITIVE RIVALRY
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 THREAT OF SUBSTITUTES
5.9 KEY STAKEHOLDERS & BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS
TABLE 5 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS (%)
5.9.2 BUYING CRITERIA
FIGURE 33 KEY BUYING CRITERIA FOR TOP 3 END USERS
TABLE 6 KEY BUYING CRITERIA FOR TOP 3 END USERS
5.10 REGULATORY LANDSCAPE
TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING TISSUE DIAGNOSTICS MARKET
5.11 PATENT ANALYSIS
5.12 KEY CONFERENCES & EVENTS IN 2022-2023
TABLE 8 LIST OF CONFERENCES & EVENTS
5.13 PRICING ANALYSIS
TABLE 9 PRICE RANGE FOR TISSUE DIAGNOSTICS
5.14 TRADE ANALYSIS
TABLE 10 IMPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 11 EXPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION)
5.15 ECOSYSTEM ANALYSIS
TABLE 12 ROLE IN ECOSYSTEM
FIGURE 34 KEY PLAYERS OPERATING IN TISSUE DIAGNOSTICS MARKET
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT (Page No. – 84)
6.1 INTRODUCTION
TABLE 13 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
6.2 CONSUMABLES
TABLE 14 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
TABLE 15 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2019–2027 (USD MILLION)
6.2.1 ANTIBODIES
TABLE 16 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2019–2027 (USD MILLION)
6.2.2 KITS
TABLE 17 TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2019–2027 (USD MILLION)
6.2.3 REAGENTS
TABLE 18 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2019–2027 (USD MILLION)
6.2.4 PROBES
TABLE 19 TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2019–2027 (USD MILLION)
6.3 INSTRUMENTS
TABLE 20 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
TABLE 21 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2019–2027 (USD MILLION)
6.3.1 SLIDE-STAINING SYSTEMS
TABLE 22 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2019–2027 (USD MILLION)
6.3.2 SCANNERS
TABLE 23 TISSUE DIAGNOSTICS MARKET FOR SCANNERS, BY REGION, 2019–2027 (USD MILLION)
6.3.3 TISSUE-PROCESSING SYSTEMS
TABLE 24 TISSUE DIAGNOSTICS MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION, 2019–2027 (USD MILLION)
6.3.4 OTHER INSTRUMENTS
TABLE 25 TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2019–2027 (USD MILLION)
7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. – 94)
7.1 INTRODUCTION
TABLE 26 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
7.2 IMMUNOHISTOCHEMISTRY (IHC)
TABLE 27 TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2019–2027 (USD MILLION)
7.3 IN SITU HYBRIDIZATION (ISH)
TABLE 28 TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2019–2027 (USD MILLION)
7.4 DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT
TABLE 29 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT, BY REGION, 2019–2027 (USD MILLION)
7.5 SPECIAL STAINING
TABLE 30 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2019–2027 (USD MILLION)
8 TISSUE DIAGNOSTICS MARKET, BY DISEASE (Page No. – 100)
8.1 INTRODUCTION
TABLE 31 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
FIGURE 35 ARTICLES PUBLISHED ON CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 32 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION)
8.2 BREAST CANCER
TABLE 33 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
FIGURE 36 ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 34 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2019–2027 (USD MILLION)
8.3 GASTRIC CANCER
TABLE 35 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
FIGURE 37 ARTICLES PUBLISHED ON GASTRIC CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 36 TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2019–2027 (USD MILLION)
8.4 LYMPHOMA
TABLE 37 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025
TABLE 38 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025
FIGURE 38 ARTICLES PUBLISHED ON LYMPHOMA TISSUE DIAGNOSTICS, 2011–2021
TABLE 39 TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2019–2027 (USD MILLION)
8.5 PROSTATE CANCER
TABLE 40 PROSTATE CANCER INCIDENCE, BY REGION, 2018 VS. 2025
FIGURE 39 ARTICLES PUBLISHED ON PROSTATE CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 41 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2019–2027 (USD MILLION)
8.6 NON-SMALL CELL LUNG CANCER
TABLE 42 NON-SMALL CELL LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
FIGURE 40 ARTICLES PUBLISHED ON NON-SMALL CELL LUNG CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 43 TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2019–2027 (USD MILLION)
8.7 OTHER DISEASES
TABLE 44 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2019–2027 (USD MILLION)
9 TISSUE DIAGNOSTICS MARKET, BY END USER (Page No. – 112)
9.1 INTRODUCTION
TABLE 45 TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
9.2 HOSPITALS
TABLE 46 TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2019–2027 (USD MILLION)
9.3 RESEARCH LABORATORIES
TABLE 47 TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2019–2027 (USD MILLION)
9.4 PHARMACEUTICAL COMPANIES
TABLE 48 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2019–2027 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
TABLE 49 ONCOLOGY CONTRACT RESEARCH ORGANIZATIONS (CROS).
TABLE 50 TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2027 (USD MILLION)
9.6 OTHER END USERS
TABLE 51 TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019–2027 (USD MILLION)
10 TISSUE DIAGNOSTICS MARKET, BY REGION (Page No. – 118)
10.1 INTRODUCTION
TABLE 52 TISSUE DIAGNOSTICS MARKET, BY REGION, 2019–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 41 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 42 TISSUE DIAGNOSTICS MARKET IN NORTH AMERICA: SNAPSHOT
TABLE 53 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 (USD MILLION)
TABLE 54 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
TABLE 57 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION)
TABLE 58 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 59 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.2.1 US
10.2.1.1 US to dominate country-level market for tissue diagnostics
TABLE 60 US CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 61 US: KEY MACROINDICATORS
TABLE 62 LIST OF US FDA-APPROVED PRODUCTS RELATED TO TISSUE DIAGNOSTICS
TABLE 63 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 64 US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 65 US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 High prevalence of cancer to support market growth
TABLE 66 CANADA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 67 CANADA: KEY MACROINDICATORS
TABLE 68 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 69 CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 70 CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3 EUROPE
FIGURE 43 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
TABLE 71 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 (USD MILLION)
TABLE 72 EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 73 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
TABLE 74 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
TABLE 75 EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION)
TABLE 76 EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 77 EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth
TABLE 78 GERMANY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 79 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 80 GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 81 GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.2 UK
10.3.2.1 Government initiatives to drive market growth
TABLE 82 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 83 UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 84 UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government funding for cancer diagnosis & prevention to support market growth
TABLE 85 FRANCE CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 86 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 87 FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 88 FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 High incidence of cancer and geriatric population to support market growth
TABLE 89 ITALY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 90 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 91 ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 92 ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 High incidence of chronic diseases to drive market growth
TABLE 93 SPAIN CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 94 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 95 SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 96 SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 97 LUNG CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040
TABLE 98 LIVER CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040
TABLE 99 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 100 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 101 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 44 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 45 TISSUE DIAGNOSTICS MARKET IN ASIA PACIFIC: SNAPSHOT
TABLE 102 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 (USD MILLION)
TABLE 103 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
TABLE 105 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
TABLE 106 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION)
TABLE 107 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 108 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Increasing healthcare expenditure and funding to drive market growth
TABLE 109 CHINA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 110 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 111 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 112 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Advanced healthcare infrastructure to support market growth
TABLE 113 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 114 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 115 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 116 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Expanding healthcare sector to drive market growth
TABLE 117 INDIA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 118 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 119 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 120 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 121 INCIDENCE OF CANCER IN REST OF ASIA PACIFIC
TABLE 122 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 123 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 124 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 125 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY REGION, 2019–2027 (USD MILLION)
TABLE 126 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 127 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
TABLE 128 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
TABLE 129 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION)
TABLE 130 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 131 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.5.1 LATIN AMERICA
10.5.1.1 Increasing number of cancer screening programs to support market growth
TABLE 132 KEY LATIN AMERICAN COUNTRIES LUNG CANCER INCIDENCE, 2018 VS. 2025
TABLE 133 KEY LATIN AMERICAN COUNTRIES LIVER CANCER INCIDENCE, 2018 VS. 2025
TABLE 134 KEY LATIN AMERICAN COUNTRIES BREAST CANCER INCIDENCE, 2018 VS. 2025
TABLE 135 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 136 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 137 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
10.5.2 MIDDLE EAST & AFRICA
10.5.2.1 Increasing incidence of cancer to support market growth
TABLE 138 AFRICA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 139 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
TABLE 140 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
TABLE 141 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. – 168)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 142 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
11.3 REVENUE SHARE ANALYSIS
FIGURE 46 REVENUE ANALYSIS OF KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
11.4 MARKET SHARE ANALYSIS
TABLE 143 TISSUE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 47 COMPANY EVALUATION QUADRANT: TISSUE DIAGNOSTICS MARKET
11.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 48 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: TISSUE DIAGNOSTICS MARKET
11.7 COMPANY FOOTPRINT ANALYSIS
11.7.1 COMPANY FOOTPRINT
11.7.2 COMPANY REGIONAL FOOTPRINT
11.7.3 COMPANY PRODUCT FOOTPRINT
11.8 COMPETITIVE BENCHMARKING
TABLE 144 TISSUE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES/APPROVALS
TABLE 145 KEY PRODUCT LAUNCHES
11.9.2 DEALS
TABLE 146 KEY DEALS
11.9.3 OTHER DEVELOPMENTS
TABLE 147 KEY OTHER DEVELOPMENTS
12 COMPANY PROFILES (Page No. – 181)
(Business Overview, Products Offered, Recent Developments, and MnM View)*
12.1 KEY PLAYERS
12.1.1 F. HOFFMANN-LA ROCHE LTD
TABLE 148 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 49 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
12.1.2 DANAHER CORPORATION
TABLE 149 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 50 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
12.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 150 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
12.1.4 ABBOTT
TABLE 151 ABBOTT: BUSINESS OVERVIEW
FIGURE 52 ABBOTT.: COMPANY SNAPSHOT (2021)
12.1.5 AGILENT TECHNOLOGIES INC.
TABLE 152 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
FIGURE 53 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2021)
12.1.6 MERCK KGAA
TABLE 153 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 54 MERCK KGAA COMPANY SNAPSHOT (2021)
12.1.7 SAKURA FINETEK JAPAN CO., LTD.
TABLE 154 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW
12.1.8 ABCAM PLC.
TABLE 155 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 55 ABCAM PLC. COMPANY SNAPSHOT (2021)
12.1.9 BECTON, DICKINSON AND COMPANY (BD)
TABLE 156 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 56 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
12.1.10 BIO SB
TABLE 157 BIO SB: BUSINESS OVERVIEW
12.1.11 BIOGENEX
TABLE 158 BIOGENEX.: BUSINESS OVERVIEW
12.1.12 CELL SIGNALING TECHNOLOGY, INC.
TABLE 159 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
12.1.13 HISTO-LINE LABORATORIES
TABLE 160 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW
12.1.14 SLEE MEDICAL GMBH
TABLE 161 SLEE MEDICAL GMBH.: BUSINESS OVERVIEW
12.1.15 AMOS SCIENTIFIC PTY LTD
TABLE 162 AMOS SCIENTIFIC PTY LTD: BUSINESS OVERVIEW
12.1.16 JINHUA YIDI MEDICAL APPLIANCE CO. LTD
TABLE 163 JINHUA YIDI MEDICAL APPLIANCE CO.LTD: BUSINESS OVERVIEW
12.1.17 MEDITE MEDICAL GMBH
TABLE 164 MEDITE MEDICAL GMBH: BUSINESS OVERVIEW
12.1.18 CELLPATH LTD
TABLE 165 CELLPATH LTD: BUSINESS OVERVIEW
12.1.19 HOLOGIC, INC
TABLE 166 HOLOGIC, INC: BUSINESS OVERVIEW
FIGURE 57 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
12.1.20 DIAPATH S.P.A.
TABLE 167 DIAPATH S.P.A.: BUSINESS OVERVIEW
12.1.21 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD
TABLE 168 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD: BUSINESS OVERVIEW
12.1.22 DIAGNOSTIC BIOSYSTEMS INC.
TABLE 169 DIAGNOSTIC BIOSYSTEMS INC.: BUSINESS OVERVIEW
12.1.23 3DHISTECH LTD.
TABLE 170 3DHISTECH LTD: BUSINESS OVERVIEW
12.1.24 RWD LIFE SCIENCE CO., LTD.
TABLE 171 RWD LIFE SCIENCE CO., LTD.: BUSINESS OVERVIEW
12.1.25 DAKEWEI BIOTECHNOLOGY CO., LTD.
TABLE 172 DAKEWEI BIOTECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13 APPENDIX (Page No. – 238)
13.1 INDUSTRY INSIGHTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
